Commercial launch strategies and defensive positioning for the U.S.
Biosimilars are entering the U.S. market, and, no matter what role a company plays in the healthcare landscape, biosimilars will be a disrupter. The key challenge companies need to face now is how they will adapt their commercial strategies to be successful. The biosimilars market will continue to evolve rapidly and with uncertainty. No matter their strategic objectives, all biopharmaceutical companies in the ecosystem need to be ever-present and stay in tune with the pulse of this disruptive and rapidly evolving market.